Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
PEPTIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
Document Type and Number:
WIPO Patent Application WO/2019/017384
Kind Code:
A1
Abstract:
The present invention provides a peptide having a structure in which a portion of a dominant-negative peptide of BIG3 which inhibits interaction between BIG3 and PHB2, is replaced by at least two stapling structures. The peptide according to the present invention has excellent cell growth inhibiting activity. The cell growth inhibiting activity is sustained for a long period of time, compared to a single-stapled peptide. Therefore, the peptide according to the present invention has a feature suitable for clinical applications in cancer therapy.

Inventors:
KATAGIRI TOYOMASA (JP)
YOSHIMARU TETSURO (JP)
MIYAMOTO TAKASHI (JP)
OKAMOTO YASUHIDE (JP)
Application Number:
PCT/JP2018/026904
Publication Date:
January 24, 2019
Filing Date:
July 18, 2018
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
UNIV TOKUSHIMA (JP)
ONCOTHERAPY SCIENCE INC (JP)
International Classes:
C07K7/08; A61K38/10; A61P13/08; A61P15/08; A61P15/14; A61P35/00; A61P43/00
Domestic Patent References:
WO2013018690A12013-02-07
WO2017126461A12017-07-27
WO2013018690A12013-02-07
WO2017012646A12017-01-26
Foreign References:
JP2016523241A2016-08-08
JP2017140101A2017-08-17
JP2017001187W2017-01-16
JP4647456B22011-03-09
Other References:
YOSHIMARU, TETSURO ET AL.: "Stapled BIG3 helical peptide ERAP potentates anti-tumour activity for breast cancer therapeutics", SCIENTIFIC REPORTS, vol. 7, no. 1821, 1 December 2017 (2017-12-01), pages 1 - 11, XP055653759, ISSN: 2045-2322, DOI: 10.1038/s41598-017-01951-6
WALENSKY, LOREN D. ET AL.: "Hydrocarbon-Stapled Peptides: Principles , Practice, and Progress", JOURNAL OF MEDICINAL CHEMISTRY, vol. 57, 2014, pages 6275 - 6288, XP055537971, DOI: 10.1021/jm4011675
See also references of EP 3656783A4
JOHNSTON, S. R., CLIN. CANCER RES., vol. 16, 2010, pages 1979 - 1987
FISHER, B. ET AL., J. NATL. CANCER INST., vol. 97, 2005, pages 1652 - 1662
JORDAN, V C., NATURE REV. DRUG DISCOV., vol. 2, 2003, pages 205 - 213
CLARKE, R. ET AL., PHARMACOL. REV., vol. 53, 2001, pages 25 - 71
FISHER, B. ET AL., J. NATL. CANCER INST., vol. 93, 2001, pages 684 - 690
CHLEBOWSKI, R. ET AL., BREAST, vol. 2, 2009, pages 1 - 11
CHUMSRI, S. ET AL., J. STEROID BIOCHEM. MOL. BIOL., vol. 125, 2011, pages 13 - 22
KIM, J. W. ET AL., CANCER SCI., vol. 100, 2009, pages 1468 - 1478
YOSHIMARU, T. ET AL., NAT. COMMUN., vol. 4, 2013, pages 2443
YOSHIMARU, T. ET AL., SCI REP., vol. 7, no. 1, 2017, pages 1821
BLACKWELL, H. E. ET AL., ANGEW. CHEM., INT. ED., vol. 37, 1994, pages 3281 - 3284
AIHARA, K. ET AL., TETRAHEDRON, vol. 71, 2015, pages 4183 - 4191
NELLES JL ET AL., EXPERT REV ENDOCRINOL METAB, vol. 6, no. 3, May 2011 (2011-05-01), pages 437 - 451
STABILE LP ET AL., CANCER RES., vol. 65, no. 4, 15 February 2005 (2005-02-15), pages 1459 - 70
MARQUEZ-GARBAN DC ET AL., STEROIDS, vol. 72, no. 2, February 2007 (2007-02-01), pages 135 - 43
NAT. GENET., vol. 45, 2013, pages 1446
CANCER DISCOV., vol. 1, no. 4, September 2011 (2011-09-01), pages 338 - 51
NATURE, vol. 490, no. 7418, 4 October 2012 (2012-10-04), pages 61 - 70
CANCER LETT., vol. 323, no. 1, 1 October 2012 (2012-10-01), pages 77 - 87
CLIN. BREAST CANCER., vol. 15, no. 3, June 2015 (2015-06-01), pages 197 - 203
NAT. COMMUN., vol. 8, 30 May 2017 (2017-05-30), pages 15427
NAT. COMMUN., vol. 8, 2017, pages 15427
SCI. REP., vol. 7, 2017, pages 1821
PROC. NATL. ACAD. SCI. USA, vol. 96, 1999, pages 6947
CELL SIGNAL, vol. 22, 2010, pages 1185
ANTICANCER RES, vol. 26, 2006, pages 4235
BREAST CANCER RES., vol. 13, 2011, pages 221
Attorney, Agent or Firm:
HARUNA, Masao et al. (JP)
Download PDF: